ArcticZymes Technologies

Mindre end 1K følgere

AZT

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

ArcticZymes Technologies is active in biotechnology. The company specializes in research and development of drugs for the treatment of autoimmune diseases. The main focus is on the development of glucans, the production of immunostimulants, and the analysis of enzymes. The vision is to test and develop the medicine and then further use it for RNA and DNA processes. The company was previously known as Biotec Pharmacon and is headquartered in Tromsø.

Læs mere

Markedsværdi

Aktieomsætning

Omsætning

112,62 mio.

EBIT %

2,5 %

P/E

Udbytteafkast, %

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.